On November 13, 2024, CEL-SCI Corporation (NYSE: CVM) announced in a recent 8-K filing with the Securities and Exchange Commission that Patricia B. Prichep, the current Senior Vice President of Operations, has taken on the role of Chief Financial and Operations Officer of the company effective the same date.
The details regarding Ms. Prichep’s new position can be accessed through CEL-SCI’s Proxy Statement concerning its 2024 Annual Meeting of Shareholders, available for review on the Securities and Exchange Commission’s website.
This change in leadership within CEL-SCI demonstrates a strategic move towards consolidating responsibilities and strengthening operational functions within the company. For more information and updates, investors and stakeholders are encouraged to follow the company’s future announcements and disclosures as part of its commitment to transparency and regulatory compliance.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read CEL-SCI’s 8K filing here.
CEL-SCI Company Profile
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
Further Reading
- Five stocks we like better than CEL-SCI
- How to Invest in Insurance Companies: A Guide
- How Whitestone REIT Is Transforming Sunbelt Retail Growth
- Bank Stocks – Best Bank Stocks to Invest In
- Top-Performing Non-Leveraged ETFs This Year
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
